TYR and Alzheimer disease: Some studies suggest that plasma ATN biomarker measurements may effectively distinguish between AD patients and healthy controls, particularly when using techniques such as Illness Management and Recovery (IMR) for plasma amyloid β and the Simoa immunoassay for p-tau18.